Monitoring levetiracetam concentration in saliva during pregnancy is stable and feasible

Wanling Li,Ximeng Yang,Qian Chen,Zhenlei Wang,Yifei Duan,Lei Chen
DOI: https://doi.org/10.1111/cns.14827
2024-07-13
CNS Neuroscience & Therapeutics
Abstract:Salivary and plasma levetiracetam concentrations had a linear relationship and similar changes during pregnancy, which supported the effective use of saliva in levetiracetam therapeutic drug monitoring during pregnancy. Aims This multicenter prospective cohort study (registration no. ChiCTR2000032089) aimed to investigate the relationship between saliva and plasma levetiracetam concentrations to determine whether saliva could be used for routine monitoring of levetiracetam during pregnancy. Methods The slot concentrations of levetiracetam in simultaneously obtained saliva and plasma samples were measured using UPLC–MS/MS. The correlations between saliva and plasma levetiracetam concentrations and the dose‐normalized concentrations were compared among pregnant women in different stages and nonpregnant control participants with epilepsy. Results In total, 231 patients with 407 plasma and saliva sample pairs were enrolled from 39 centers. Linear relationships between salivary and plasma levetiracetam concentrations were reported in the enrolled population (r = 0.898, p
pharmacology & pharmacy,neurosciences
What problem does this paper attempt to address?